Theralase Technologies (TSXV: TLT)

Theralase® Technologies is a Canadian clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds and their associated drug formulations intended to safely and effectively destroy various cancers. We strive to continuously improve the quality of life for those afflicted with cancer by focusing our research and development on preventing, alleviating and treating diseases. Serving our higher purpose to bring hope for cancer treatments to light. Founded in 1994, Theralase’s operations are divided into two divisions: the production of therapeutic laser technology for commercial applications, and the research and development of laser-based technologies for the destruction of cancer cells and other disease states. Theralase® is focused on the discovering, developing and aiming for commercialization of Anti-Cancer therapies using light-activated PhotoDynamic Compounds and their associated drug formulations to safely and effectively treat patients afflicted with cancer.